Physician profile
Flavia Mendes
NPI 1487628582
$6,086.81
in general payments reported to CMS, 2019-2025
16 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $3,837 · 2021: $924 · 2022: $256 · 2023: $111 · 2024: $320 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $4,677.97 | 2020-2024 | Ocaliva |
| Abbvie INC. | $408.82 | 2019-2025 | |
| Gilead Sciences, INC. | $197.48 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.33 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $119.45 | 2025 | |
| Phathom Pharmaceuticals, INC. | $117.00 | 2024 | Voquezna |
| Qol Medical, LLC | $91.96 | 2022-2025 | Sucraid, Sucraid |
| Allergan, INC. | $60.21 | 2019-2020 | |
| Dova Pharmaceuticals | $57.81 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $46.44 | 2024-2025 | Iqirvo |
| Braintree Laboratories, INC. | $44.81 | 2019 | |
| Redhill Biopharma INC. | $34.48 | 2022 | |
| Ironwood Pharmaceuticals, INC | $20.45 | 2023 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $18.91 | 2022 | |
| Janssen Biotech, INC. | $14.41 | 2024 | Stelara |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $14.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flavia Mendes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.